Covered recipient · General Payments record
JAMES KEVIN MCCLOSKEY
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$615,903.99
426 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $400,395.00 | 100 |
| Travel and Lodging | $81,014.17 | 166 |
| Honoraria | $79,782.00 | 38 |
| Consulting Fee | $48,063.05 | 20 |
| Food and Beverage | $6,649.77 | 102 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| GlaxoSmithKline, LLC. | $132,147.32 | 61 |
| Takeda Pharmaceuticals U.S.A., Inc. | $106,542.24 | 51 |
| Blueprint Medicines Corporation | $92,950.75 | 104 |
| SOBI, INC | $66,714.16 | 33 |
| E.R. Squibb & Sons, L.L.C. | $38,518.03 | 27 |
| JAZZ PHARMACEUTICALS INC. | $36,137.08 | 24 |
| PharmaEssentia USA Corporation | $30,789.49 | 18 |
| Amgen Inc. | $30,343.27 | 21 |
| Rigel Pharmaceuticals, Inc. | $23,344.49 | 12 |
| Incyte Corporation | $19,604.58 | 18 |
| Stemline Therapeutics Inc. | $19,404.11 | 14 |
| Geron Corporation | $8,016.76 | 4 |
| ABBVIE INC. | $5,482.66 | 10 |
| Karyopharm Therapeutics Inc. | $2,575.48 | 2 |
| TAIHO ONCOLOGY, INC. | $2,431.92 | 6 |
| Celgene Corporation | $683.58 | 7 |
| Daiichi Sankyo Inc. | $72.53 | 5 |
| Novartis Pharmaceuticals Corporation | $50.11 | 3 |
| Alexion Pharmaceuticals, Inc. | $30.58 | 2 |
| Astellas Pharma US Inc | $18.61 | 1 |
| PFIZER INC. | $16.35 | 1 |
| Bard Peripheral Vascular, Inc. | $15.32 | 1 |
| Adaptive Biotechnologies Corporation | $14.57 | 1 |
Page 8 of 9; records 351–400 of 426 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
JAMES KEVIN MCCLOSKEY
NPI 1992951149 · CMS profile ID 648059
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
HACKENSACK, NJ
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 8 of 9; records 351–400 of 426 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1992951149?year=2024&recipient=provider&page=8#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- JAMES KEVIN MCCLOSKEY, NPI 1992951149, CMS profile ID 648059. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 9; records 351–400 of 426 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992951149?year=2024&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). JAMES KEVIN MCCLOSKEY, NPI 1992951149, CMS profile ID 648059. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 9; records 351–400 of 426 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992951149?year=2024&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- JAMES KEVIN MCCLOSKEY, NPI 1992951149, CMS profile ID 648059, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 9; records 351–400 of 426 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1992951149?year=2024&recipient=provider&page=8#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
426 matching records · $615,903.99 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 351–400 of 426.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Incyte Corporation | $545.00 | 03/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1141274204 | CMS |
| Rigel Pharmaceuticals, Inc. | $1,713.00 | 03/14/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145201756 | CMS |
| GlaxoSmithKline, LLC. | $457.97 | 03/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115954049 | CMS |
| GlaxoSmithKline, LLC. | $204.75 | 03/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116452619 | CMS |
| JAZZ PHARMACEUTICALS INC. | $5,580.00 | 03/13/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150241544 | CMS |
| JAZZ PHARMACEUTICALS INC. | $458.42 | 03/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150241546 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $111.15 | 03/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144962698 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $259.52 | 03/12/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144962700 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $318.58 | 03/12/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144962702 | CMS |
| Blueprint Medicines Corporation | $254.22 | 03/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447458 | CMS |
| Blueprint Medicines Corporation | $433.10 | 03/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447460 | CMS |
| Blueprint Medicines Corporation | $80.00 | 03/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447462 | CMS |
| Blueprint Medicines Corporation | $188.75 | 03/08/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447464 | CMS |
| Blueprint Medicines Corporation | $321.53 | 03/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447466 | CMS |
| Blueprint Medicines Corporation | $129.12 | 03/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447468 | CMS |
| GlaxoSmithKline, LLC. | $895.70 | 03/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116286393 | CMS |
| Blueprint Medicines Corporation | $79.49 | 03/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447470 | CMS |
| Blueprint Medicines Corporation | $1,041.00 | 03/04/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447424 | CMS |
| GlaxoSmithKline, LLC. | $778.10 | 02/29/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1116394974 | CMS |
| JAZZ PHARMACEUTICALS INC. | $247.19 | 02/29/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150241562 | CMS |
| Blueprint Medicines Corporation | $1,008.00 | 02/28/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447426 | CMS |
| Celgene Corporation | $15.78 | 02/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101134826 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $5,495.00 | 02/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144962696 | CMS |
| Blueprint Medicines Corporation | $121.06 | 02/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447570 | CMS |
| Rigel Pharmaceuticals, Inc. | $21.97 | 02/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145201754 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,581.69 | 02/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144962694 | CMS |
| Blueprint Medicines Corporation | $1,008.00 | 02/21/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447428 | CMS |
| Blueprint Medicines Corporation | $3,528.00 | 02/21/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447544 | CMS |
| Blueprint Medicines Corporation | $546.20 | 02/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447546 | CMS |
| Blueprint Medicines Corporation | $80.00 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447548 | CMS |
| Blueprint Medicines Corporation | $108.59 | 02/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447550 | CMS |
| Blueprint Medicines Corporation | $61.22 | 02/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447560 | CMS |
| Blueprint Medicines Corporation | $92.15 | 02/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447562 | CMS |
| Blueprint Medicines Corporation | $94.94 | 02/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447564 | CMS |
| Blueprint Medicines Corporation | $41.79 | 02/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447566 | CMS |
| Blueprint Medicines Corporation | $21.89 | 02/21/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447568 | CMS |
| GlaxoSmithKline, LLC. | $4,800.00 | 02/20/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1115739775 | CMS |
| JAZZ PHARMACEUTICALS INC. | $679.33 | 02/16/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150241542 | CMS |
| TAIHO ONCOLOGY, INC. | $16.82 | 02/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137941626 | CMS |
| ABBVIE INC. | $291.34 | 02/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104996189 | CMS |
| ABBVIE INC. | $144.00 | 02/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104996191 | CMS |
| Blueprint Medicines Corporation | $5,292.00 | 02/14/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447430 | CMS |
| Blueprint Medicines Corporation | $262.76 | 02/14/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447432 | CMS |
| Blueprint Medicines Corporation | $35.02 | 02/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447434 | CMS |
| ABBVIE INC. | $211.00 | 02/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104996185 | CMS |
| ABBVIE INC. | $297.00 | 02/13/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104996187 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $813.56 | 02/10/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1144962692 | CMS |
| Blueprint Medicines Corporation | $3,780.00 | 02/07/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447472 | CMS |
| Blueprint Medicines Corporation | $4,284.00 | 02/07/2024 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447474 | CMS |
| Blueprint Medicines Corporation | $362.42 | 02/07/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1147447476 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $3,470,967.33 | 1,676 |
| PY2024 | Principal investigator | $762,085.86 | 415 |
| PY2023 | Principal investigator | $2,162,906.61 | 182 |
| PY2022 | Principal investigator | $2,026,330.52 | 185 |
| PY2021 | Recipient | $4,442.10 | 1 |
| PY2021 | Principal investigator | $4,208,118.88 | 127 |
| PY2020 | Recipient | $8,925.50 | 1 |
| PY2020 | Principal investigator | $991,151.35 | 80 |
| PY2019 | Recipient | $15,053.40 | 1 |
| PY2019 | Principal investigator | $702,962.50 | 95 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
1,676 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,800.00 | 12/22/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417137 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $11,416.81 | 12/19/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418529 |
| Principal investigator 1 | Servier BioInnovation | $2,252.25 | 12/16/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | No dispute reported | 06/30/2026 | 1235965338 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $500.00 | 12/11/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609393 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $200.00 | 12/11/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609397 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,250.00 | 12/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350122 |
| Principal investigator 1 | Servier BioInnovation | $551.00 | 12/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | No dispute reported | 06/30/2026 | 1235965336 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $45,977.61 | 12/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211414983 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $842.00 | 12/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104154 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $3,004.00 | 12/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104167 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $15,827.22 | 12/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417827 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,374.00 | 12/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418539 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $400.00 | 12/03/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663491 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,378.75 | 12/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419239 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,855.24 | 12/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211414981 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349920 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349930 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349936 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349940 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349944 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349968 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349982 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349988 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349998 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350008 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350014 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350020 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350022 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350032 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350044 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350052 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350062 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350066 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350074 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350076 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350080 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350096 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350100 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350118 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350136 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350138 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350156 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 12/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350178 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $270.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) | No dispute reported | 06/30/2026 | 1246782119 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $4,455.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) | No dispute reported | 06/30/2026 | 1246782123 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608456 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608459 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608463 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608466 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608471 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608476 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608480 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608483 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608487 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608491 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608495 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608498 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608501 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608504 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608508 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608512 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608516 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608520 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608524 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608527 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608531 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608536 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608540 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608544 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608548 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608551 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608555 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608559 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608562 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608567 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608570 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608573 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608578 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608582 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608584 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608588 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608591 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608596 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608599 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608603 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608607 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608610 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608612 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608615 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608619 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608622 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608626 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608630 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608634 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608638 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608642 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608646 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608650 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608653 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608657 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608660 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608663 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608666 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608671 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608677 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608681 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608684 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608688 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608692 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608696 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608698 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608701 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608705 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608709 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608714 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608717 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608721 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608725 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608729 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608731 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608734 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608738 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608742 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608745 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608749 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608753 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608758 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608763 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608766 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608770 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608775 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608779 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608783 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608787 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608792 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608795 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608799 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608804 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608809 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608813 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608819 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608823 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608827 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608830 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608834 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608837 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608842 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608846 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608849 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608853 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608856 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608860 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608864 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608868 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608874 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608878 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608882 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608885 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608889 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608893 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608896 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608900 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608904 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608907 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608911 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608915 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608919 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608923 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608927 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608931 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608936 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608941 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608944 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608948 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608950 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608954 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608959 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608964 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608968 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608972 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608975 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608979 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608984 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608988 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608993 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608997 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609001 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609004 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609008 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609012 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609016 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609020 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609024 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609028 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609033 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609036 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609040 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609044 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609048 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609052 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609056 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609060 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609065 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609069 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609073 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609076 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609080 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609084 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609088 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609092 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609095 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609098 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609101 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609105 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609109 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609113 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609117 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609120 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609125 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609129 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609133 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609137 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609140 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609145 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609147 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609152 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609156 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609161 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609164 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609169 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609172 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609176 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609181 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609184 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609188 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609191 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609197 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609200 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609203 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609208 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609212 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609215 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609219 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609223 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609226 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609230 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609234 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609237 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609240 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609244 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609248 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609251 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609254 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609258 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609261 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609265 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609268 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609272 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609276 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609279 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609282 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609286 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609290 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609294 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609299 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609302 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609306 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609310 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609313 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609317 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609320 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609323 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609327 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609331 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609334 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609339 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609342 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609347 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609351 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609355 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609358 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609362 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609367 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609371 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609374 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609379 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609382 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609386 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 12/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176609389 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,669.10 | 11/27/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) | No dispute reported | 06/30/2026 | 1223266529 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,750.00 | 11/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349914 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $250.00 | 11/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350172 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,122.20 | 11/21/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) | No dispute reported | 06/30/2026 | 1246782114 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $9,357.12 | 11/14/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418527 |
| Principal investigator 1 | Genmab U.S., Inc. | $2,750.00 | 11/13/2025 | Covered Recipient Teaching Hospital Jfk University Medical Center | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | No dispute reported | 06/30/2026 | 1235923888 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349896 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349898 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349904 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349908 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349924 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349926 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349932 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,904.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349934 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349938 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349942 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349946 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349948 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349950 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349952 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349954 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349956 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,167.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349958 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $393.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349962 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349966 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349970 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349972 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,143.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349974 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $393.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349976 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349990 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349992 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349994 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349996 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350002 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350004 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350012 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350016 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350018 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350024 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350026 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350028 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350034 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350040 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350042 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350048 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350050 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350056 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350060 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350070 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350082 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350084 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350086 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,904.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350088 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350092 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350094 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,650.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350098 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,538.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350112 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350114 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,437.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350116 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350120 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,538.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350124 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350128 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350132 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,143.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350144 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350152 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350154 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350160 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350164 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350174 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350186 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,425.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350188 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350190 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,812.00 | 11/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350192 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $41,275.63 | 11/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418531 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $250.00 | 11/06/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608449 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,800.00 | 11/06/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608452 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,122.20 | 11/05/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) | No dispute reported | 06/30/2026 | 1246782108 |
| Principal investigator 1 | ABBVIE INC. | $3,989.00 | 11/04/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis | No dispute reported | 06/30/2026 | 1202411974 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $19.50 | 11/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349900 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.75 | 11/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349912 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $100.30 | 11/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349916 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.50 | 11/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350036 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $125.00 | 11/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350140 |
| Principal investigator 1 | Servier BioInnovation | $477.75 | 11/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | No dispute reported | 06/30/2026 | 1235965334 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,374.00 | 10/27/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415768 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $18,565.59 | 10/27/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417163 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $250.00 | 10/23/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608447 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,855.24 | 10/17/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211417161 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,090.00 | 10/17/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) | No dispute reported | 06/30/2026 | 1223266523 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $5,237.73 | 10/13/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419973 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349902 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349910 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349918 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,425.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349922 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,748.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349928 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349964 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349978 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,143.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349980 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349984 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349986 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350000 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350030 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350038 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350046 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350054 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350058 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350064 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350068 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350072 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350078 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350090 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350104 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350106 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,143.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350108 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350110 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,355.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350130 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350142 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,425.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350146 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,748.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350148 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,143.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350150 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350158 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350162 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350166 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,143.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350168 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350170 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350176 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350180 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350182 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350184 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350194 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 10/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350196 |
| Principal investigator 1 | Servier BioInnovation | $792.00 | 10/07/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | No dispute reported | 06/30/2026 | 1235965332 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $4,060.00 | 10/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104162 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $575.00 | 10/02/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663412 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $852.00 | 10/02/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663446 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $103.00 | 10/02/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663565 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $600.00 | 10/02/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608438 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $173.72 | 10/02/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608443 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $750.00 | 10/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419995 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349906 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349960 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 10/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350006 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350010 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350102 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 10/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350126 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 10/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350134 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $7,713.00 | 10/01/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL GROUP UROLOGY | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190299475 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608119 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608122 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608126 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608130 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608135 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608139 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608142 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608146 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608150 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608154 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608158 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608163 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608167 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608171 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608175 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608177 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608181 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608184 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608189 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608193 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608197 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608200 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608204 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608209 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608212 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608216 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608219 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608224 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608228 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608232 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608236 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608240 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608243 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608247 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608252 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608256 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608261 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608266 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608269 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608272 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608276 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608279 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608283 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608287 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608289 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608293 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608296 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608299 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608303 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608307 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608311 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608314 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608318 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608321 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608326 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608329 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608333 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608337 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608343 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608346 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608351 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608354 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608359 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608363 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608366 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608369 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608372 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608376 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608379 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608384 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608388 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608390 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608395 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608400 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608405 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608409 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608414 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608418 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608422 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608426 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608430 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 10/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608434 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $115.79 | 09/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349612 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $13,231.55 | 09/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419985 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,000.00 | 09/17/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL CENTER | EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1192177324 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $544.38 | 09/16/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608107 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $544.38 | 09/16/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608111 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $544.38 | 09/16/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608115 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,282.86 | 09/16/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211418545 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,179.08 | 09/15/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211415746 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $680.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349424 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $354.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349426 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,036.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349428 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,268.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349430 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $128.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349500 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8,366.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349502 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $404.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349504 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $296.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349506 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $33,220.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349526 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $492.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349528 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $630.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349530 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $34,314.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349532 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $38,745.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349534 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,320.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349536 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,309.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349538 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $504.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349540 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,502.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349542 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $114.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349544 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $855.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349546 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $882.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349548 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $952.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349550 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,155.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349552 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,536.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349554 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,740.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349556 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $198.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349558 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $116.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349560 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $84.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349562 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $665.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349564 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $804.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349566 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $54,000.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349568 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $770.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349570 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,025.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349832 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $802.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349838 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $290.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349866 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $170.00 | 09/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349880 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $206.49 | 09/11/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608099 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,200.00 | 09/11/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608103 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $78.79 | 09/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418543 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $5,076.00 | 09/09/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) | No dispute reported | 06/30/2026 | 1246782102 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,425.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349390 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349434 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349436 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349438 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349440 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349448 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349452 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349454 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349456 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349458 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,143.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349462 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349464 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349466 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349470 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349472 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349478 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349482 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,143.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349484 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349486 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349488 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349490 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349492 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349494 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349496 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349678 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349680 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,167.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349682 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,437.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349684 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349686 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,354.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349688 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349690 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349692 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,538.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349694 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349742 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349744 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349746 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349748 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349750 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349828 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349836 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,538.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349842 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349844 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349848 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349854 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349864 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349872 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349876 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 09/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349892 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $261.48 | 09/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349398 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $40.62 | 09/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349498 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $500.00 | 09/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349738 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $800.00 | 09/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349740 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,520.00 | 09/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663410 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $600.00 | 09/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663495 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $3,202.00 | 09/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663537 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 09/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663555 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 09/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349608 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $234.40 | 09/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211415748 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $340.00 | 09/02/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608096 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607596 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607600 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607604 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607607 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607611 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607616 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607620 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607623 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607627 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607631 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607634 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607638 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607641 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607645 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607648 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607652 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607656 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607660 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607664 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607669 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607671 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607674 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607677 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607681 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607686 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607689 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607693 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607696 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607700 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607704 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607707 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607713 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607717 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607721 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607726 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607729 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607733 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607736 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607740 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607744 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607749 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607753 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607757 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607761 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607765 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607770 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607774 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607777 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607780 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607784 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607788 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607792 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607797 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607801 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607805 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607809 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607813 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607817 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607821 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607825 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607830 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607833 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607837 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607841 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607844 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607847 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607851 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607855 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607859 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607863 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607867 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607871 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607875 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607879 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607884 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607888 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607892 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607895 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607900 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607904 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607907 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607912 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607916 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607920 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607925 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607929 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607932 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607937 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607941 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607945 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607949 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607953 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607956 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607960 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607964 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607967 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607971 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607975 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607979 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607984 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607988 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607991 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607996 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608000 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608003 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608007 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608011 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608015 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608019 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608023 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608026 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608030 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608034 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608038 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608042 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608045 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608049 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608053 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608057 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608061 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608065 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608069 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608072 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608076 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608080 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608084 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608088 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 09/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176608092 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $3,621.78 | 09/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211414989 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $1,200.00 | 08/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | C-906289-002 | No dispute reported | 06/30/2026 | 1249030049 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $164.69 | 08/28/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607592 |
| Principal investigator 1 | ABBVIE INC. | $588.00 | 08/25/2025 | Covered Recipient Teaching Hospital JFK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202413337 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $250.00 | 08/22/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211419241 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $692.63 | 08/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211414979 |
| Principal investigator 1 | ABBVIE INC. | $3,750.00 | 08/19/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis | No dispute reported | 06/30/2026 | 1202411971 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $75.00 | 08/18/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) | No dispute reported | 06/30/2026 | 1246782099 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,800.00 | 08/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211416442 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,085.95 | 08/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417141 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $544.38 | 08/15/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607585 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,622.00 | 08/15/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607589 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $491.13 | 08/14/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607581 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $34,263.27 | 08/14/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211416438 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $250.00 | 08/13/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211416440 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,207.79 | 08/13/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211419237 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,122.20 | 08/12/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) | No dispute reported | 06/30/2026 | 1246782095 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $544.38 | 08/12/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607572 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,622.00 | 08/12/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607577 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,427.62 | 08/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211414987 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,498.00 | 08/07/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607555 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $750.00 | 08/07/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607560 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $15,275.00 | 08/07/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607565 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,872.00 | 08/07/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607569 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $183.32 | 08/06/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211418537 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $11.55 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349392 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $12.75 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349394 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349400 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349402 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349404 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349406 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349408 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349410 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349412 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349414 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349576 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349578 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349580 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349592 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349594 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349596 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349610 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349716 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349718 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349720 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349722 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349724 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349726 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349728 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349730 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349732 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349734 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349736 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349752 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349754 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349756 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349758 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349760 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349762 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349764 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349766 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349768 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349770 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349772 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349774 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349776 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349778 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349780 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349782 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349784 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349786 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349822 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349830 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $25.00 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349834 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349850 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349858 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349860 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $6.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349874 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349878 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349882 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349886 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349888 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 08/05/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349894 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,090.00 | 08/05/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL CENTER | EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1192177320 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,762.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349396 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349416 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349418 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,167.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349420 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,650.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349422 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349696 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349698 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349700 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349702 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349704 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349706 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,650.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349708 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349710 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,167.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349712 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349714 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349788 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349790 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349792 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349794 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349796 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349798 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349800 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349802 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349804 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349806 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349808 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349810 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349812 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349814 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $856.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349824 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349840 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,748.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349868 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 08/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349890 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $73.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663408 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $675.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663422 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $103.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663426 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $103.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663436 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $405.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663444 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $24.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663450 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663452 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $103.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663454 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $103.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663470 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $600.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663474 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $96.20 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663482 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $87.75 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663505 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $3,467.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663507 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $103.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663513 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,520.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663515 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $201.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663525 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663529 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $103.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663533 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $201.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663541 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $3,247.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663553 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $24.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663561 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $405.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663563 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $103.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663567 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $103.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663587 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $201.00 | 08/04/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663589 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $3,000.00 | 08/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104148 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607299 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607303 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607307 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607311 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607315 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607319 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607323 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607327 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607331 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607335 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607339 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607343 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607347 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607351 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607354 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607359 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607363 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607367 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607371 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607375 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607379 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607383 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607387 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607391 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607394 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607399 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607403 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607407 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607410 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607413 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607416 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607420 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607424 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607427 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607432 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607437 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607441 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607445 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607450 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607453 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607456 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607461 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607464 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607467 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607471 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607474 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607477 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607480 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607485 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607489 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607491 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607495 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607498 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607502 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607505 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607510 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607514 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607519 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607522 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607527 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607530 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607533 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607537 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607541 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607546 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 08/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607550 |
| Principal investigator 1 | ABBVIE INC. | $588.00 | 07/30/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis | No dispute reported | 06/30/2026 | 1202411963 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,641.00 | 07/28/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) | No dispute reported | 06/30/2026 | 1246782090 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $7,243.56 | 07/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211416436 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $216.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349614 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,902.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349616 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $177.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349618 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,148.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349620 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $136.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349622 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $401.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349624 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,251.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349626 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $126.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349628 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349630 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $315.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349632 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $12,706.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349634 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $271.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349636 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,160.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349638 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $357.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349640 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $246.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349642 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $58.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349644 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $165.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349646 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,025.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349648 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $95.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349650 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $616.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349652 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $256.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349654 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $296.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349656 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $204.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349658 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $231.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349660 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $85.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349662 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $84.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349664 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $189.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349820 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $32.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349846 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,535.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349870 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $19,096.43 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | C-906289-002 | No dispute reported | 06/30/2026 | 1249030037 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $1,200.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | C-906289-002 | No dispute reported | 06/30/2026 | 1249030042 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $11,510.00 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | C-906289-002 | No dispute reported | 06/30/2026 | 1249030047 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $3,178.03 | 07/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211414977 |
| Principal investigator 1 | Servier BioInnovation | $897.00 | 07/22/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | No dispute reported | 06/30/2026 | 1235965330 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,100.00 | 07/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349856 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $9,304.45 | 07/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211419233 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,427.62 | 07/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211419235 |
| Principal investigator 1 | ABBVIE INC. | $300.00 | 07/15/2025 | Covered Recipient Teaching Hospital JFK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202413321 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $337.50 | 07/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417825 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,159.00 | 07/11/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) | No dispute reported | 06/30/2026 | 1223266519 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,122.20 | 07/10/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) | No dispute reported | 06/30/2026 | 1246782087 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $1,000.00 | 07/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104086 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $1,900.00 | 07/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104093 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $1,750.00 | 07/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104097 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $1,500.00 | 07/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104105 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $4,100.00 | 07/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104110 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $3,250.00 | 07/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104115 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $2,750.00 | 07/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104122 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $1,250.00 | 07/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104129 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $3,000.00 | 07/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104136 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $8,250.00 | 07/10/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244104142 |
| Principal investigator 1 | ABBVIE INC. | $3,600.00 | 07/09/2025 | Covered Recipient Teaching Hospital JFK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202413317 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349508 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,748.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349510 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,748.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349512 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349514 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349516 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349518 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349520 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,748.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349522 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349524 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,650.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349572 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,167.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349574 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,538.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349582 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,447.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349584 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,425.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349586 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,904.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349588 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349590 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,425.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349598 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,904.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349600 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,538.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349602 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349604 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,447.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349606 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349666 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349668 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349670 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,143.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349672 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,355.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349674 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349676 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,200.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349816 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,100.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349818 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349852 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349862 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349884 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $89.47 | 07/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417135 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $7,437.15 | 07/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417823 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,187.00 | 07/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419979 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,100.00 | 07/07/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349432 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,250.00 | 07/07/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211419231 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $291.89 | 07/07/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211419981 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $10,865.34 | 07/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417821 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,520.00 | 07/03/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663420 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $462.00 | 07/03/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663458 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 07/03/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663478 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $600.00 | 07/03/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663547 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,374.00 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211414973 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,374.00 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211414975 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $12,757.50 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415744 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,374.00 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211416434 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,187.00 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417813 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $8,680.50 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417815 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $16,230.09 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417817 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $25,879.50 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417819 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,374.00 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418533 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,561.00 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418535 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,561.00 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419227 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $19,765.35 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419229 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $12,757.50 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419975 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $7,272.45 | 07/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419977 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 07/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349442 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 07/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349444 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349446 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 07/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349450 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 07/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349460 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 07/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349468 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 07/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349474 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 07/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349476 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $31.00 | 07/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349480 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $8.85 | 07/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349826 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607105 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607109 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607113 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607118 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607122 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607127 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607132 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607136 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607141 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607145 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607149 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607153 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607156 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607160 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607165 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607168 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607172 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607177 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607180 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607183 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607187 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607191 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607195 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607200 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607204 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607207 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607211 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607214 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607217 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607223 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607227 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607231 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607233 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607238 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607241 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607245 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607250 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607254 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607258 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607262 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607266 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607271 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607275 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607279 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607283 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607287 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607291 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 07/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607295 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $544.38 | 06/27/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607098 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,622.00 | 06/27/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607102 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $5,076.00 | 06/26/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL CENTER | EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1192175473 |
| Principal investigator 1 | Genmab U.S., Inc. | $400.00 | 06/24/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | No dispute reported | 06/30/2026 | 1235930300 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $46,711.76 | 06/23/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211416448 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $90.39 | 06/23/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211417159 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $600.00 | 06/23/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211419253 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $250.00 | 06/20/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350633 |
| Principal investigator 1 | Genmab U.S., Inc. | $756.95 | 06/19/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | No dispute reported | 06/30/2026 | 1235930304 |
| Principal investigator 1 | Ionis Pharmaceuticals, Inc. | $2,122.20 | 06/19/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 702843 Administered to Patients With Phlebotomy Dependent Polycythemia Vera (PD-PV) | No dispute reported | 06/30/2026 | 1246782081 |
| Principal investigator 1 | ABBVIE INC. | $2,800.00 | 06/18/2025 | Covered Recipient Teaching Hospital JFK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202413313 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $5,854.00 | 06/18/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607093 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,200.00 | 06/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419989 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,194.47 | 06/16/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211417837 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,376.00 | 06/12/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607087 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,023.00 | 06/12/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607090 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349250 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349252 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349254 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349256 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,259.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349258 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349260 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,437.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349262 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,437.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349264 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349266 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349294 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,904.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349296 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349332 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $393.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349334 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349336 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,143.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349338 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,235.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349340 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349342 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,538.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349350 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,447.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349352 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349356 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349358 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349360 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349362 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349364 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,425.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349370 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349374 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349378 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349384 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349386 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349388 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,800.00 | 06/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211419987 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $300.00 | 06/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415760 |
| Principal investigator 1 | ABBVIE INC. | $4,370.08 | 06/05/2025 | Covered Recipient Teaching Hospital JFK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202413310 |
| Principal investigator 1 | Genmab U.S., Inc. | $960.00 | 06/05/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | No dispute reported | 06/30/2026 | 1235930287 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,400.00 | 06/05/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | No dispute reported | 06/30/2026 | 1235930295 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 06/05/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES | No dispute reported | 06/30/2026 | 1223266517 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $172,901.25 | 06/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211419251 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,520.00 | 06/02/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663414 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $462.00 | 06/02/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663448 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 06/02/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663539 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $400.00 | 06/02/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663549 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $600.00 | 06/02/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663583 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $3,621.78 | 06/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211414993 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $61,023.95 | 05/30/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | C-906289-002 | No dispute reported | 06/30/2026 | 1249029901 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $4,370.00 | 05/30/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | C-906289-002 | No dispute reported | 06/30/2026 | 1249029904 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $3,000.00 | 05/30/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | C-906289-002 | No dispute reported | 06/30/2026 | 1249029909 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $800.00 | 05/29/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607083 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,500.00 | 05/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417835 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,000.00 | 05/26/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES | No dispute reported | 06/30/2026 | 1223266513 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $7,054.19 | 05/22/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417153 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $8,747.56 | 05/22/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418559 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,600.00 | 05/22/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419249 |
| Principal investigator 1 | ABBVIE INC. | $1,350.00 | 05/20/2025 | Covered Recipient Teaching Hospital JFK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202413290 |
| Principal investigator 1 | ABBVIE INC. | $55,944.01 | 05/20/2025 | Covered Recipient Teaching Hospital JFK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202413294 |
| Principal investigator 1 | ABBVIE INC. | $2,400.00 | 05/20/2025 | Covered Recipient Teaching Hospital JFK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202413297 |
| Principal investigator 1 | ABBVIE INC. | $895.00 | 05/20/2025 | Covered Recipient Teaching Hospital JFK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202413302 |
| Principal investigator 1 | ABBVIE INC. | $3,146.85 | 05/20/2025 | Covered Recipient Teaching Hospital JFK UNIVERSITY MEDICAL CENTER | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis | No dispute reported | 06/30/2026 | 1202413306 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $2,000.00 | 05/16/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | C-906289-002 | No dispute reported | 06/30/2026 | 1249029913 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $3,000.00 | 05/16/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | C-906289-002 | No dispute reported | 06/30/2026 | 1249029921 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $1,800.00 | 05/16/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | C-906289-002 | No dispute reported | 06/30/2026 | 1249029924 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,508.22 | 05/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211419993 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,864.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349280 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,425.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349282 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,538.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349284 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349286 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,447.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349288 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349290 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349298 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349300 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349302 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,748.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349304 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349306 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349308 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,518.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349310 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349312 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,748.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349314 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,437.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349316 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,812.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349318 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,609.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349320 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349322 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349324 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349326 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,812.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349328 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349330 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,904.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349368 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,170.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349376 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $748.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349380 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 05/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349382 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $250.00 | 05/08/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607079 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 05/05/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663442 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,520.00 | 05/05/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663468 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $9,404.00 | 05/05/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663493 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 05/05/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663577 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $250.00 | 05/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349354 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $8,559.00 | 05/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211415766 |
| Principal investigator 1 | Servier BioInnovation | $1,033.50 | 05/01/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | No dispute reported | 06/30/2026 | 1235965328 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606638 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606642 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606647 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606653 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606657 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606662 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606665 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606669 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606673 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606677 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606681 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606685 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606689 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606693 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606697 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606701 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606704 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606707 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606711 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606714 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606717 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606721 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606725 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606729 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606734 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606738 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606742 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606746 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606751 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606755 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606759 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606763 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606766 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606770 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606774 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606778 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606781 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606785 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606790 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606794 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606798 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606801 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606805 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606808 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606814 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606817 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606821 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606825 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606829 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606833 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606838 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606843 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606847 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606850 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606855 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606857 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606861 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606864 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606868 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606872 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606876 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606880 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606885 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606889 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606894 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606898 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606903 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606908 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606912 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606917 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606920 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606923 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606927 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606931 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606934 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606939 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606942 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606947 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606951 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606955 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606958 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606963 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606967 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606970 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606974 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606979 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606982 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606984 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606988 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606991 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606994 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606999 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607002 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607006 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607010 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607013 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607016 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607020 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607025 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607028 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607032 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607036 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607040 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607044 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607049 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607053 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607057 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607061 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607066 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607071 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 05/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176607076 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,800.00 | 04/30/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211414991 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $49,964.90 | 04/28/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418557 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $55,209.61 | 04/24/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL GROUP UROLOGY | A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocyt | No dispute reported | 06/30/2026 | 1190307231 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $30,550.00 | 04/24/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606634 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $58,351.18 | 04/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211417157 |
| Principal investigator 1 | ABBVIE INC. | $1,726.00 | 04/17/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy | No dispute reported | 06/30/2026 | 1202411931 |
| Principal investigator 1 | Genmab U.S., Inc. | $500.00 | 04/17/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | No dispute reported | 06/30/2026 | 1235930284 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $13,122.00 | 04/15/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417833 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $27,615.03 | 04/15/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418555 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,885.00 | 04/14/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211415764 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $21,219.30 | 04/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417149 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,561.00 | 04/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417151 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $2,623.50 | 04/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419247 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349268 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349270 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $868.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349272 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,538.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349274 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349276 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,904.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349278 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,167.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349292 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,650.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349344 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,285.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349346 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,355.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349348 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $250.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349366 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,447.00 | 04/09/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349372 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $76.52 | 04/08/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417147 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,000.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663416 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,500.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663428 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $250.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663432 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,000.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663456 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,000.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663460 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $600.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663466 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,720.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663480 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,000.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663486 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $4,000.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663488 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,900.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663501 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $600.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663509 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $600.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663521 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $3,000.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663527 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,720.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663531 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $6,450.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663535 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,500.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663543 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $3,100.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663575 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,550.00 | 04/07/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663579 |
| Principal investigator 1 | Genmab U.S., Inc. | $19,496.50 | 04/04/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | No dispute reported | 06/30/2026 | 1235930292 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,860.00 | 04/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415754 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $242.57 | 04/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415756 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,255.50 | 04/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415758 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,561.00 | 04/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417831 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $18,351.00 | 04/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418549 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $30,388.50 | 04/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418551 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $270.00 | 04/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418553 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,200.00 | 04/04/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419245 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $8,976.15 | 04/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211416444 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,500.00 | 04/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211416446 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,200.00 | 04/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417143 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $14,015.70 | 04/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417145 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $281.54 | 04/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417829 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $4,374.00 | 04/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418547 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $19,575.00 | 04/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211419243 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $750.00 | 04/02/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211419991 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606501 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606504 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606507 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606511 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606514 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606518 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606522 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606526 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606530 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606533 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606537 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606540 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606544 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606547 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606551 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606555 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606559 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606563 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606567 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606571 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606575 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606581 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606584 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606587 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606591 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606595 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606598 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606603 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606607 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606610 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606615 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606619 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606623 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $95.50 | 04/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606626 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $237.62 | 03/25/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244119022 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,689.00 | 03/24/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES | No dispute reported | 06/30/2026 | 1223266511 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $3,639.00 | 03/21/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A RANDOMIZED, OPEN-LABEL, PHASE 2 TRIAL OF PONATINIB IN PATIENTS WITH RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA TO CHARACTERIZE THE EFFICACY AND SAFETY OF A RANGE OF DOSES | No dispute reported | 06/30/2026 | 1223266509 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $10.60 | 03/18/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244118990 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $85.99 | 03/18/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244118996 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $175.82 | 03/18/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244119002 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $20.90 | 03/18/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244119009 |
| Principal investigator 1 | Stemline Therapeutics Inc. | $46.60 | 03/18/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL CENTER - JOHN THEURER CANCER C | STML-401-0423 - A PHASE II MULTICENTER OPEN -LABEL TRIAL OF TAGRAXOFUSP (TAG) IN COMBINATION WITH VENETOCLAX AND AZACITIDINE (VEN/AZA) IN ADULTS WITH PREVIOUSLY UNTREATED CD123+ ACUTE MYELOID LEUKEMIA (AML) WHO ARE INELIGIBLE FOR INTENSIVE CHEMOTHERAPY | No dispute reported | 06/30/2026 | 1244119016 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $364,605.57 | 03/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211414985 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $250.00 | 03/18/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211419983 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $12,800.00 | 03/17/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350214 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $4,000.00 | 03/17/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350216 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,900.00 | 03/17/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350218 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,000.00 | 03/17/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350220 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,750.00 | 03/17/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350222 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,250.00 | 03/17/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350224 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,000.00 | 03/17/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350228 |
| Principal investigator 1 | ABBVIE INC. | $2,100.00 | 03/13/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | M20-178 - Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis | No dispute reported | 06/30/2026 | 1202411909 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,425.00 | 03/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350198 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,748.00 | 03/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350200 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,029.00 | 03/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350202 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $5,748.00 | 03/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350204 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,538.00 | 03/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350206 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,447.00 | 03/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350208 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $1,904.00 | 03/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350210 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $2,489.00 | 03/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350212 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $3,425.00 | 03/12/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223350226 |
| Principal investigator 1 | Genmab U.S., Inc. | $9,700.00 | 03/06/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | No dispute reported | 06/30/2026 | 1235930272 |
| Principal investigator 1 | Genmab U.S., Inc. | $4,800.00 | 03/06/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | No dispute reported | 06/30/2026 | 1235930280 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,520.00 | 03/06/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663430 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 03/06/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663476 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349126 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349128 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349130 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349132 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349134 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349136 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $57.75 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349138 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $69.30 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349140 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $150.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349142 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349144 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349146 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349148 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349150 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349152 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $15.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349154 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $150.45 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349156 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $24.95 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349158 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.70 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349160 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.70 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349162 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.70 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349164 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349166 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $34.65 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349168 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349170 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349172 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349174 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349176 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349178 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349180 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349182 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349184 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349186 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349188 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349190 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349192 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349194 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349196 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349198 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349200 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349202 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349204 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349206 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349208 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349210 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349212 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349214 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $46.50 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349216 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349218 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349220 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349222 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349224 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349226 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349228 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349230 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $12.75 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349232 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $124.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349234 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $124.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349236 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $29.25 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349238 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349240 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $62.00 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349242 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $17.70 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349244 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $35.40 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349246 |
| Principal investigator 1 | Daiichi Sankyo Inc. | $26.55 | 03/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | AC220-168 | No dispute reported | 06/30/2026 | 1223349248 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606319 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606323 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606327 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606331 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606336 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606339 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606343 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606347 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606350 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606353 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606358 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $16.20 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606361 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606365 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606367 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606371 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606374 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606378 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606382 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606386 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606392 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606395 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606401 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606404 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606408 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606412 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606414 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606417 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606420 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606424 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606429 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606432 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606439 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606443 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606447 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606451 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606455 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606460 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606464 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606467 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606470 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606473 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606478 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606481 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606486 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.50 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606490 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606492 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $95.50 | 03/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606496 |
| Principal investigator 1 | Servier BioInnovation | $2,304.00 | 02/25/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | No dispute reported | 06/30/2026 | 1235965326 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $21,824.88 | 02/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211417155 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $56,050.95 | 02/21/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY COMPARING PONATINIB VERSUS IMATINIB, ADMINISTERED IN COMBINATION WITH REDUCED-INTENSITY CHEMOTHERAPY, IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (PH+ ALL) | No dispute reported | 06/30/2026 | 1223266507 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $20,346.85 | 02/20/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211415752 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $7,381.29 | 02/19/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211418561 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,000.00 | 02/14/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL CENTER | EXTENDED ACCESS OF MOMELOTINIB FOR SUBJECTS WITH PRIMARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1192175478 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $1,563.30 | 02/14/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | An Open-Label, Multicenter, Extension Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) | No dispute reported | 06/30/2026 | 1211415750 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,200.00 | 02/13/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606315 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,593.00 | 02/12/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663418 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $462.00 | 02/12/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663424 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,726.00 | 02/12/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663462 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $5,631.00 | 02/12/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663497 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 02/12/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663511 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,520.00 | 02/12/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663517 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $11,328.00 | 02/12/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663523 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,053.00 | 02/12/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663559 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,520.00 | 02/12/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663571 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,520.00 | 02/12/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663573 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $2,053.00 | 02/12/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663585 |
| Principal investigator 1 | Servier BioInnovation | $1,436.50 | 02/11/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | No dispute reported | 06/30/2026 | 1235965324 |
| Principal investigator 1 | Rigel Pharmaceuticals, Inc. | $2,750.00 | 02/07/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | C-906289-002 | No dispute reported | 06/30/2026 | 1249029917 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $2,602.00 | 01/30/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606311 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,800.00 | 01/24/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211416450 |
| Principal investigator 1 | Genmab U.S., Inc. | $7,625.51 | 01/23/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | No dispute reported | 06/30/2026 | 1235930268 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,200.00 | 01/23/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606307 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $175.19 | 01/23/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211417139 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $306.31 | 01/23/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Multi-phase, Dose-Escalation Followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) | No dispute reported | 06/30/2026 | 1211418541 |
| Principal investigator 1 | Servier BioInnovation | $1,972.00 | 01/21/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | SAFETY STUDY OF AG-120 OR AG-221 IN COMBINATION WITH INDUCTION AND CONSOLIDATION THERAPY IN PARTICIPANTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 AND/OR IDH2 MUTATION | No dispute reported | 06/30/2026 | 1235965322 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $535.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663434 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663438 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $87.75 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663440 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663464 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $462.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663472 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $675.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663484 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $1,000.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663499 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663503 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663519 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $81.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663545 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663551 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $165.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663557 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663569 |
| Principal investigator 1 | Karyopharm Therapeutics Inc. | $527.00 | 01/20/2025 | Non-covered Recipient Entity Hackensack University Medical Center a Division of HMH Hospitals Corporation_034-0036 | A Phase 2 Study to Evaluate the Efficacy and Safety of Selinexor in Patients with High-Risk Myelofibrosis | No dispute reported | 06/30/2026 | 1246663581 |
| Principal investigator 1 | ABBVIE INC. | $2,706.25 | 01/16/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | M20-178 - Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed Refractory Myelofibrosis | No dispute reported | 06/30/2026 | 1202411877 |
| Principal investigator 1 | TAIHO ONCOLOGY, INC. | $6,582.38 | 01/06/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | ASTX727-07 | No dispute reported | 06/30/2026 | 1211415762 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $15,113.65 | 01/03/2025 | Covered Recipient Teaching Hospital Hackensack University Medical Center | A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo in Subjects with Myeloproliferative Neoplasm- Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blo | No dispute reported | 06/30/2026 | 1236001116 |
| Principal investigator 1 | Genmab U.S., Inc. | $445.39 | 01/03/2025 | Non-covered Recipient Entity HACKENSACK MERIDIAN HEALTH HACKENSACK UNIVERSITY MEDICAL CENTER | An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies. | No dispute reported | 06/30/2026 | 1235930276 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $369,460.21 | 01/01/2025 | Non-covered Recipient Entity HACKENSACK UNIVERSITY MEDICAL GROUP UROLOGY | A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia | No dispute reported | 06/30/2026 | 1190307223 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606153 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606156 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $43.70 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606160 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606164 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606167 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606171 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606175 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606179 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606183 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606187 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $0.25 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606191 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $95.50 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606197 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606201 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606205 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606209 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606212 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606215 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606219 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $8.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606223 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606227 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606230 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606236 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606239 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606242 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606247 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606250 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606252 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606258 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606262 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606265 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606269 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $14.10 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606273 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606277 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606280 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606284 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606287 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606291 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606294 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606297 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $24.00 | 01/01/2025 | Covered Recipient Teaching Hospital HACKENSACK UNIVERSITY MEDICAL CENTER | A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS | No dispute reported | 06/30/2026 | 1176606303 |